CytoMed Therapeutics (GDTC) Short-Term Debt to Equity
This price chart for CytoMed Therapeutics (GDTC) reflects a debt-to-equity ratio of 0.02. The Singapore-based business develops NK-cell therapies for oncology centers, targeting the global medical segment. Efficiency is enhanced by outsourcing trials to external CRO networks, which minimizes risks. Meanwhile, unique cell modification methods ensure seamless production scaling and global market capture.
%3A%20Short-Term%20Debt%20to%20Capital%20Ratio&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_GDTC_-_CytoMed-Therapeutics_-_Short-Term-Debt-to-Capital-Ratio "w2.cytomed.sg - GDTC Short-Term Debt to Capital (period 02/21/2024 - 10/30/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for CytoMed (GDTC)
- stock quotes and analyst forecast:
- market capitalization details:
- balance sheet equity data:
- business debt structure and liquidity details:
Debt to Equity CytoMed Therapeutics|GDTC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio CytoMed Therapeutics|GDTC - Aggregate Debt Obligations|Debts to Book Capitalization CytoMed Therapeutics Ltd|GDTC - Company Long-Term Liabilities|Company Current Liabilities CytoMed Therapeutics|Quick Liquidity w2.cytomed.sg
- earnings and market ratios statistics:
Fundamental valuation:CytoMed Therapeutics Limited
This ratio compares the volume of liabilities with a maturity of up to one year against total equity, determining the company's degree of dependence on short-term debt financing. By analyzing the current short-term debt to equity value, an investor assesses liquidity risk, which is critical for CytoMed Therapeutics (GDTC) when implementing costly robotic biochemical screening systems to accelerate preclinical trials.
Competitors of CytoMed Therapeutics
Short-Term Debt to Capital ONC|Short-Term Debt to Capital Halozyme Corp (HALO)|Short-Term Debt to Equity Revolution Medicines RVMD|AAPG: Short-Term Debt to Capital Ratio|CG Oncology - Short-Term Debt to Capital|UroGen Pharma Ltd (URGN) - Short-Term Debt to Equity Ratio|BCAX: Short-Term Debt to Capital|Current Liabilities to Capital Personalis Genomics (PSNL)|Short-Term Debt to Equity Erasca, Inc.|DCTH: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio YMAB (Y-mAbs Therapeutics, Inc.)|AURA (Aura Biosciences Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital CADL (Candel Therapeutics, Inc.)|ARAY - Short-Term Debt to Equity Ratio|SLS: Short-Term Debt to Equity Ratio|ACTU - Short-Term Debt to Capital|Citius Oncology (CTOR) - Short-Term Debt to Equity|TuHURA Biosciences - Ratio of Short-Term Indebtedness to Capital|TARA (Protara) - Short-Term Debt to Capital|Current Liabilities to Capital Fate Pharma FATE|Short-Term Debt to Capital WHWK|Short-Term Debt to Equity Ratio tscan.com TCRX|Champions Oncology, Inc. - Short-Term Debt to Equity Ratio|XBiotech Inc (XBIT) - Current Liabilities to Capital|CVM: Short-Term Debt to Equity Ratio|OS Therapies, Inc. - Short-Term Loans to Capital Ratio|Radiopharm Theranostics (RADX) - Short-Term Debt to Equity|Current Liabilities to Capital Artiva Biotherapeutics (ARTV)|Short-Term Debt to Equity Adlai Nortye Ltd|Short-Term Debt to Equity Ratio Veru Inc (VERU)|Short-Term Debt to Capital TPST|XLO - Current Liabilities to Capital|Short-Term Debt to Capital RENB (Renovaro)|MURA: Short-Term Debt to Capital Ratio|KAPA: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital OKUR (OnKure Therapeutics Inc)|CRIS (curis.com) - Short-Term Debt to Equity Ratio|APLM: Short-Term Loans to Capital Ratio|THAR (Tharimmune, Inc.) - Short-Term Debt to Capital|ADVB: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital GNPX|CLDI - Current Liabilities to Capital|Short-Term Debt to Equity Sunshine Biopharma SBFM|Ratio of Short-Term Indebtedness to Capital XBIO|Salarius Pharmaceuticals - Short-Term Debt to Capital|PPBT - Short-Term Debt to Capital|aoncology.com (AONC) - Short-Term Debt to Equity|Current Liabilities to Equity BGNE (BeiGene Ltd.)|CKPT (Checkpoint Therapeutics, Inc) - Short-Term Debt to Capital|Current Liabilities to Capital Elevation Oncology Inc. ELEV|Short-Term Debt to Equity Ratio ICAD (iCAD, Inc.)|Short-Term Debt to Capital ikenaoncology.com (IKNA)|Notable Labs - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio VIRX (Viracta Therapeutics Inc.)|MorphoSys Corp - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient NAYA Biosciences Corp NAYA|AAPGV: Short-Term Debt to Capital